Karyopharm Therapeutics Inc Stock Price, News & Analysis

Karyopharm Therapeutics (Nasdaq: KPTI), a leader in cancer therapies, announced that CEO Richard Paulson will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 1:40 p.m. ET. A live webcast will be available in the Investor section of their website, with replays accessible for 90 days. Karyopharm specializes in oral Selective Inhibitor of Nuclear Export (SINE) technology, including its approved drug XPOVIO®. The company's pipeline targets multiple high unmet need cancer indications.

Karyopharm Therapeutics (Nasdaq: KPTI) reported strong financial results for Q4 2021, with net product revenue of $29.8 million, a 47% increase year-over-year. Total revenue for 2021 reached $209.8 million, up from $108.1 million in 2020. They achieved significant milestones, including a commercialization partnership with Menarini and positive data from the SIENDO study on selinexor. However, the company reported a net loss of $124.1 million for 2021. For 2022, Karyopharm expects XPOVIO revenue between $135 million and $145 million.

Karyopharm Therapeutics (Nasdaq: KPTI) reported positive results from its Phase 3 SIENDO study on selinexor for patients with advanced or recurrent endometrial cancer. The study involved 263 patients and achieved a median progression-free survival (PFS) of 5.7 months with selinexor, compared to 3.8 months for placebo, marking a 50% improvement. The drug showed a 30% reduction in disease progression risk. Particularly, patients with wild-type p53 saw a median PFS of 13.7 months. Karyopharm plans to submit a supplemental New Drug Application to the FDA in H1 2022.

Karyopharm Therapeutics (KPTI) will report its fourth quarter and full year 2021 financial results on February 8, 2022. Management will hold a conference call at 8:30 a.m. ET on the same day to discuss the results and updates. Karyopharm is known for its novel cancer therapies, including the first-in-class XPO1 inhibitor, XPOVIO®, and has a focused pipeline targeting high unmet needs in cancer treatments. Interested parties can access the call via phone or a live audio webcast on the company's website.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the grant of stock options for 124,500 shares to 15 newly-hired employees, effective January 31, 2022. The exercise price is set at $8.90 per share, reflecting the stock's closing price on the grant date. Options will vest over four years, with 25% vesting after one year and the remainder monthly. The options are also subject to immediate exercise if the employee's role is terminated without cause within a year following a 'change in control.' This move aligns with Nasdaq rules for inducements to new hires.

Karyopharm Therapeutics (Nasdaq: KPTI) announced the FDA granted orphan drug designation for eltanexor, a novel oral SINE compound, aimed at treating myelodysplastic syndromes (MDS). This designation supports the development of therapies for conditions affecting fewer than 200,000 patients annually, offering incentives such as potential market exclusivity. Eltanexor has shown a 53% overall response rate in clinical trials for HMA-refractory MDS, significantly improving survival rates compared to standard treatments. Karyopharm remains focused on advancing its clinical trials to provide new options for patients.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that President and CEO Richard Paulson will present virtually at the B. Riley Securities Oncology Investor Conference on January 28, 2022, at 9:30 a.m. ET. Investors can access a live webcast of the presentation under the 'Events & Presentations' section of Karyopharm's website. The company specializes in innovative cancer therapies and is known for its lead compound, XPOVIO® (selinexor), which has received multiple regulatory approvals. For more details, visit www.karyopharm.com.

Karyopharm Therapeutics (Nasdaq: KPTI) has announced the promotion of Sohanya Cheng to Chief Commercial Officer, effective immediately. Cheng's role includes directing the company's commercial strategy, particularly the ongoing commercialization of XPOVIO® (selinexor). With 18 years of experience in oncology and significant contributions to Karyopharm's revenue increase in 2021, her leadership is anticipated to strengthen the company’s market position. Karyopharm continues to focus on expanding its oncology portfolio and preparing for forthcoming clinical trial results.

Karyopharm Therapeutics (Nasdaq: KPTI) reported preliminary unaudited net product revenues of approximately $29.7 million for Q4 2021 and $98.3 million for the full year. The company is focused on advancing its pipeline with upcoming results from the Phase 3 SIENDO study for selinexor in advanced endometrial cancer expected this quarter. Karyopharm aims to increase sales and adoption of XPOVIO in multiple myeloma and has partnered with Menarini for further commercialization. Notable 2021 achievements include gaining conditional marketing authorization in Europe and the UK for NEXPOVIO.